Payment overview · 2025
General Payments
$617.61
30 reported records · 8 companies
Healthcare provider profile · identity verified
Jaye Krubally
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GARLAND, TX · NPI 1093132482
Verified facts
What the public records show
CMS Open Payments records show Jaye Krubally received $617.61 in general payments during 2025 across 30 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $166.96 | 27.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.18 | 24.0% | 13 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $121.84 | 19.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $67.24 | 10.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.95 | 9.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.59 | 3.3% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $17.65 | 2.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.20 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.61 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $166.96 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $148.18 | 13 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $67.24 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.95 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acetaminophen-Codeine | Acetaminophen With Codeine | 291 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 248 | 68 |
| Gabapentin | Gabapentin | 164 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 161 | 52 |
| Montelukast Sodium | Montelukast Sodium | 158 | 55 |
| Lisinopril | Lisinopril | 153 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 39 |
| Tramadol Hcl | Tramadol Hcl | 142 | 25 |
| Metformin Hcl | Metformin Hcl | 141 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 38 |
| Mounjaro | Tirzepatide | 133 | 27 |
| Trazodone Hcl | Trazodone Hcl | 118 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 50 |
| Simvastatin | Simvastatin | 111 | 38 |
| Meloxicam | Meloxicam | 110 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 27 |
| Trulicity | Dulaglutide | 82 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 26 |
| Carvedilol | Carvedilol | 69 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Losartan Potassium | Losartan Potassium | 62 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 16 |
| Prednisone | Prednisone | 57 | 29 |
| Naproxen | Naproxen | 54 | 21 |
| Ozempic | Semaglutide | 54 | 11 |
| Omeprazole | Omeprazole | 51 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 20 |
| Azithromycin | Azithromycin | 50 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 19 |
| Diazepam | Diazepam | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 25 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 12 |
| Nystatin | Nystatin | 39 | 15 |
| Allopurinol | Allopurinol | 36 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Famotidine | Famotidine | 33 | 13 |
| Ibuprofen | Ibuprofen | 33 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Furosemide | Furosemide | 29 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 22 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Acetic Acid | Acetic Acid | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.61 · 30 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, DAYBUE, FREESTYLE LIBRE 3, LYBALVI, Natroba, Spinosad, TRELEGY ELLIPTA, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error